What Dova Pharmaceuticals Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Jeffs Roger | Director | Nov 12 | Disposition to Issuer · D | −66,993 | — | — | 0 |
| Zaccardelli David | President & CEO | Nov 12 | Disposition to Issuer · D | −76,647 | — | — | 0 |
| Manning Paul B | Director | Nov 12 | Tender Offer · U | −1,783,226 | $27.50 | −$49M | 0 |
| Manning Paul B | Director | Nov 12 | Tender Offer · U | −12,979,016 | $27.50 | −$357M | 0 |
| Stalfort Sean | Director | Nov 12 | Tender Offer · U | −635,665 | $27.50 | −$17.5M | 0 |
| Novak Alfred J | Director | Nov 12 | Disposition to Issuer · D | −6,901 | — | — | 0 |
| Wysenski Nancy | Director | Nov 12 | Disposition to Issuer · D | −6,274 | — | — | 0 |
| Perceptive Advisors Llc | 10% owner | Nov 12 | Other Transaction · J | −3,125,851 | — | — | 0 |
| Hahn Mark W | Chief Financial Officer | Nov 12 | Disposition to Issuer · D | −9,024 | — | — | 0 |
| Laliberte Kevin | Sr. VP, Product Development | Nov 12 | Disposition to Issuer · D | −4,761 | — | — | 0 |
| Hoitt Jason | Chief Commercial Officer | Nov 12 | Disposition to Issuer · D | −9,970 | — | — | 0 |
| Goldman Steven M. | Director | Nov 12 | Disposition to Issuer · D | −5,000 | — | — | 0 |
| Goldman Steven M. | Director | Nov 12 | Disposition to Issuer · D | −144,280 | — | — | 0 |
| Allen Lee F Md PhD | Chief Medical Officer | Nov 12 | Disposition to Issuer · D | −9,635 | — | — | 0 |
| Zaccardelli David | President & CEO | Oct 01 | Disclosed 10b5-1 sale · S | −5,275 | $27.90 | −$147K | 76,647 |
| Hoitt Jason | Chief Commercial Officer | Sep 30 | Disclosed 10b5-1 sale · S | −2,387 | $28.00 | −$66.8K | 9,970 |
| Allen Lee F Md PhD | Chief Medical Officer | Sep 30 | Disclosed 10b5-1 sale · S | −978 | $28.00 | −$27.4K | 9,635 |
| Laliberte Kevin | Sr. VP, Product Development | Sep 30 | Disclosed 10b5-1 sale · S | −596 | $28.00 | −$16.7K | 4,761 |
| Laliberte Kevin | Sr. VP, Product Development | Sep 30 | Disclosed 10b5-1 sale · S | −3,100 | $28.00 | −$86.8K | 5,357 |
| Hahn Mark W | Chief Financial Officer | Sep 30 | Disclosed 10b5-1 sale · S | −775 | $28.00 | −$21.7K | 9,024 |
Loading...
